Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market

Executive Summary

FDA approved Johnson & Johnson's IL-23 blocker guselkumab July 13; the drug will be priced at an annual wholesale acquisition cost of $58,100, roughly in line with the currently marketed IL-17 blocker Cosentyx.

Advertisement

Related Content

Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand
Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed
2Q Pharma Results Preview: Novartis And J&J Lead The Pack
J&J Forges Ahead In Immunology Despite Competitive Dynamics
Formulary Focus: Cosentyx Navigating Tightly Managed Psoriasis Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099136

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel